Hemostemix Inc. (HEM.V)
- Previous Close
0.0500 - Open
0.0400 - Bid 0.0400 x --
- Ask 0.0450 x --
- Day's Range
0.0400 - 0.0450 - 52 Week Range
0.0400 - 0.1750 - Volume
82,500 - Avg. Volume
31,462 - Market Cap (intraday)
4.041M - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Apr 24, 2024 - Apr 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
hemostemix.comRecent News: HEM.V
Performance Overview: HEM.V
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HEM.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HEM.V
Valuation Measures
Market Cap
4.49M
Enterprise Value
8.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.77
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-165.67%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.17M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
377.59k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.66M
Company Insights: HEM.V
HEM.V does not have Company Insights